Results 1 to 10 of about 56,526 (222)
PLoS ONE, 2011 BackgroundBetacellulin (BTC), a member of the epidermal growth factor family, is known to play an important role in regulating growth and differentiation of pancreatic beta cells.
Yoon Sin Oh +4 more
doaj +2 more sources
Cell Death and Disease, 2022 Triple-negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of receptor tyrosine kinase ErbB-2/HER2.
Santiago Madera +18 more
doaj +1 more source
Journal of Cardiothoracic Surgery, 2021 Objective C-erbB-2 has been confirmed to be an oncogene that participates in cell growth, differentiation and division of tumors. We are wondered if its silenced expression can exert an anti-tumor effect. Therefore, this study is conducted to investigate
Zhigao Niu +4 more
doaj +1 more source
Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition. [PDF]
PLoS ONE, 2012 Growth factors activating the ErbB receptors have been described in prostate tumors. The androgen dependent prostate cancer cell line, LNCaP, expresses the ErbB-1, ErbB-2 and ErbB-3 receptor tyrosine kinases.
Eran Schmukler +3 more
doaj +1 more source
The ErbB Signaling Network and Its Potential Role in Endometrial Cancer
Epigenomes, 2023 Endometrial cancer (EC) is the second most common malignancy of the female reproductive system worldwide. The updated EC classification emphasizes the significant role of various signaling pathways such as PIK3CA-PIK3R1-PTEN and RTK/RAS/β-catenin in EC ...
Georgios Androutsopoulos +6 more
doaj +1 more source
Co-conserved features associated with cis regulation of ErbB tyrosine kinases. [PDF]
PLoS ONE, 2010 BACKGROUND: The epidermal growth factor receptor kinases, or ErbB kinases, belong to a large sub-group of receptor tyrosine kinases (RTKs), which share a conserved catalytic core.
Amar Mirza +3 more
doaj +1 more source
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
Breast Cancer: Targets and Therapy, 2021 Mohamad Adham Salkeni,1 Wajeeha Rizvi,2 Kyaw Hein,3 Gerald M Higa4 1Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; 2Department of Internal Medicine, West Virginia University ...
Salkeni MA, Rizvi W, Hein K, Higa GM
doaj
C-erbB-2 in Serum of Patients Receiving Fractionated Paclitaxel Chemotherapy
The International Journal of Biological Markers, 1999 Humanized anti-c-erbB-2 antibodies (Herceptin®) in a weekly schedule are a new therapeutic option for the treatment of c-erbB-2-positive, advanced breast cancer (ABC).
D. Lüftner, S. Schnabel, K. Possinger
doaj +1 more source
ErbB polymorphisms: Insights and implications for response to targeted cancer therapeutics
Frontiers in Genetics, 2015 Advances in high-throughput genomic-scanning have expanded the repertory of genetic variations in DNA sequences encoding ErbB tyrosine kinase receptors in humans, including single nucleotide polymorphisms (SNPs), polymorphic repetitive elements ...
Moulay A Alaoui-Jamali +2 more
doaj +1 more source
C-erbB-2 Oncoprotein in Gastric Carcinoma: Correlation with Clinical Stage and Prognosis
The International Journal of Biological Markers, 2001 The aim of this study was to investigate the expression of the oncogene c-erbB-2 in gastric tumors. Immunohistochemical study of the expression of c-erbB-2 was performed in formalin-fixed, paraffin-embedded sections from 82 gastric adenocarcinomas using ...
C.T.F. Oshima +3 more
doaj +1 more source